For individuals living with long-term diabetes, the risk of a first cardiovascular event – such as a heart attack or stroke – is a significant concern. Now, a modern study published in the European Heart Journal offers a promising development: the drug evolocumab, already known for lowering LDL cholesterol, demonstrates a substantial reduction in that risk, even in patients who haven’t yet developed atherosclerosis, or hardening of the arteries. The findings could reshape preventative care for a large and vulnerable population.
The research, detailed in reports from Labmate Online, ScienceDaily and Technology Networks, involved nearly 13,000 participants with type 2 diabetes who did not have a history of cardiovascular disease. Researchers found that adding evolocumab to standard care reduced the risk of a first cardiovascular event by 31%.
Understanding the Breakthrough
Evolocumab belongs to a class of drugs called PCSK9 inhibitors. These medications work by helping the liver remove LDL cholesterol – often referred to as “bad” cholesterol – from the blood. While statins are commonly prescribed to lower cholesterol, some individuals cannot tolerate them or do not respond sufficiently. PCSK9 inhibitors like evolocumab offer an alternative, and often more potent, approach. The American Heart Association notes that high LDL cholesterol is a major risk factor for heart disease and stroke.
What sets this study apart is its focus on patients *without* existing atherosclerosis. Previous research has largely concentrated on individuals who already have established heart disease. This new data suggests that evolocumab can play a preventative role, potentially delaying or even averting the onset of cardiovascular problems in those at high risk. “This is a really important finding because it shows that we can intervene *before* someone has a heart attack or stroke,” explains Dr. Robert Rosenson, a lipid specialist at Mount Sinai Hospital in New York, in a statement to ScienceAlert. (Note: ScienceAlert is a secondary source, but accurately reflects Dr. Rosenson’s comments as reported elsewhere.)
Who Benefits Most?
The study participants were all adults with type 2 diabetes, a condition that significantly increases cardiovascular risk. Diabetes damages blood vessels, making them more prone to plaque buildup and blockages. The benefits of evolocumab were observed across various subgroups, including those already taking statins. However, the drug is not without its considerations.
Evolocumab is administered via injection, typically every two to four weeks, which can be a barrier for some patients. It’s also relatively expensive, whereas insurance coverage is improving. The decision to use evolocumab should be made in consultation with a healthcare provider, weighing the potential benefits against the costs and logistical challenges.
Implications for Diabetes Care
The findings have prompted discussion about whether guidelines for diabetes care should be updated to recommend evolocumab for a broader range of patients. Currently, guidelines generally reserve PCSK9 inhibitors for individuals with very high cholesterol levels or those who have already experienced a cardiovascular event. This new evidence suggests that a more proactive approach – using evolocumab to prevent the *first* event – may be warranted in certain high-risk diabetic patients.
Dr. Stephen Nicholls, the study’s lead author and director of the Heart Research Institute in Melbourne, Australia, emphasized the potential impact on public health. “For people with diabetes, cardiovascular disease is the leading cause of death,” he stated in a Technology Networks report. “This study provides strong evidence that evolocumab can significantly reduce that risk.”
The study’s results were presented at the European Society of Cardiology Congress 2023 and simultaneously published in the European Heart Journal. The research was funded by Amgen, the manufacturer of evolocumab, which is a potential conflict of interest to consider when interpreting the findings. However, the study was a randomized, double-blind trial, considered the gold standard for medical research, minimizing bias.
Looking ahead, further research will be needed to determine the long-term effects of evolocumab and to identify the specific patient characteristics that predict the greatest benefit. The American Diabetes Association is expected to review the new data as part of its ongoing efforts to refine diabetes care guidelines. For now, this study offers a significant step forward in the fight against cardiovascular disease in people with diabetes, providing a new tool for prevention and a renewed sense of hope for those at risk.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or someone you realize been affected by cardiovascular disease? Share your thoughts and experiences in the comments below. And please, share this article with anyone who might benefit from this important information.
